

**IMPORTANT INSULIN DELIVERY DEVICE INFORMATION:  
DISCONTINUATION OF SEVERAL INSULIN DELIVERY DEVICES.**



**October 2009**

Dear Pharmacist:

We would like to inform you that after careful consideration, Novo Nordisk Inc. is discontinuing several insulin delivery devices. These devices include **Novolin<sup>®</sup> InnoLet<sup>®</sup>** disposable prefilled insulin syringes and **Novolin<sup>®</sup> PenFill<sup>®</sup>** 3mL insulin cartridges. After this discontinuation, your pharmacy may continue to stock **Novolin<sup>®</sup> InnoLet<sup>®</sup>** disposable prefilled insulin syringes and **Novolin<sup>®</sup> PenFill<sup>®</sup>** 3mL insulin cartridges, but you will not receive any new inventory. Final date of sale of the products is December 31, 2009. Please discuss this information with your patients who are currently using the following specific products:

- **Novolin<sup>®</sup> R InnoLet<sup>®</sup>** (Regular, Human Insulin Injection [recombinant DNA origin] in a 3 mL disposable prefilled insulin syringe)
- **Novolin<sup>®</sup> N InnoLet<sup>®</sup>** (NPH, Human Insulin Isophane Suspension [recombinant DNA origin] in a 3 mL disposable prefilled insulin syringe)
- **Novolin<sup>®</sup> 70/30 InnoLet<sup>®</sup>** (70% NPH, Human Insulin Isophane Suspension and 30% Regular, Human Insulin Injection [recombinant DNA origin] in a 3 mL disposable prefilled insulin syringe)
- **Novolin<sup>®</sup> R PenFill<sup>®</sup>** 3 mL cartridges (Regular, Human Insulin Injection [recombinant DNA origin])
- **Novolin<sup>®</sup> N PenFill<sup>®</sup>** 3 mL cartridges (NPH, Human Insulin Isophane Suspension [recombinant DNA origin])
- **Novolin<sup>®</sup> 70/30 PenFill<sup>®</sup>** 3 mL cartridges (70% NPH, Human Insulin Isophane Suspension and 30% Regular, Human Insulin Injection [recombinant DNA origin])

Novo Nordisk Inc. is informing all healthcare professionals and patients using these products about this action. We are also encouraging patients to speak with you about other insulin delivery options.

**What alternative insulin delivery system could be an option for appropriate patients?**

**FlexPen<sup>®</sup>** disposable insulin pens prefilled with insulin analogs may be an appropriate option for many of your patients. **FlexPen<sup>®</sup>** is available prefilled with 300 units of **Levemir<sup>®</sup>** (insulin detemir [rDNA origin] injection), **NovoLog<sup>®</sup>** (insulin aspart [rDNA origin] injection), or **NovoLog<sup>®</sup> Mix 70/30** (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin]). **FlexPen<sup>®</sup>** is the world's #1 selling prefilled insulin pen.<sup>1</sup> **NovoFine<sup>®</sup> 32G Tip** disposable needles, our thinnest needle available, are recommended for use with **FlexPen<sup>®</sup>**.\*

If you have any questions about the discontinuation of these products or alternate Novo Nordisk treatment options, please call **1-800-727-6500**.

Sincerely,

Novo Nordisk Inc.

If you do not want to be included in future mailings or communications from Novo Nordisk or would like to stop use of your information by Novo Nordisk please call 1-800-727-6500.

**References:** 1. IMS Health Inc. IMS MIDAS (12 months ending September 2008).

\*Needles are sold separately and may require a prescription in some states.

FlexPen<sup>®</sup>, InnoLet<sup>®</sup>, Levemir<sup>®</sup>, NovoFine<sup>®</sup>, Novolin<sup>®</sup>, NovoLog<sup>®</sup>, and PenFill<sup>®</sup> are registered trademarks of Novo Nordisk A/S. ©2009 Novo Nordisk Inc. Printed in the U.S.A. 138654-R1 October 2009

**BEING DISCONTINUED**



**Novolin<sup>®</sup> R InnoLet<sup>®</sup>**  
NDC# 0169-2313-21

**Novolin<sup>®</sup> N InnoLet<sup>®</sup>**  
NDC# 0169-2314-21

**Novolin<sup>®</sup> 70/30 InnoLet<sup>®</sup>**  
NDC# 0169-2317-21



**Novolin<sup>®</sup> R PenFill<sup>®</sup>**  
NDC# 0169-3473-18



**Novolin<sup>®</sup> N PenFill<sup>®</sup>**  
NDC# 0169-3474-18



**Novolin<sup>®</sup> 70/30 PenFill<sup>®</sup>**  
NDC# 0169-3477-18